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Sung Wook Kim1*, Anni-Maria Pulkki-Brannstrom1,2 and Jolene Skordis-Worrall1,3Abstract
Background: Harm reduction strategies commonly include needle and syringe programmes (NSP), opioid
substitution therapy (OST) and interventions combining these two strategies. Despite the proven effectiveness of
harm-reduction strategies in reducing human immunodeficiency virus (HIV) infection among injecting drug users
(IDUs), no study has compared the cost-effectiveness of these interventions, nor the incremental cost effectiveness
of combined therapy. Using data from the Global Fund, this study compares the cost-effectiveness of harm reduction
strategies in Eastern Europe and Central Asia, using the Ukraine as a case study.
Methods: A Markov Monte Carlo simulation is carried out using parameters from the literature and cost data from the
Global Fund. Effectiveness is presented as both QALYs and infections averted. Costs are measured in 2011 US dollars.
Results: The Markov Monte Carlo simulation estimates the cost-effectiveness ratio per infection averted as $487.4 [95%
CI: 488.47-486.35] in NSP and $1145.9 [95% CI: 1143.39-1148.43] in OST. Combined intervention is more costly but more
effective than the alternative strategies with a cost effectiveness ratio of $851.6[95% CI: 849.82-853.55].
The ICER of the combined strategy is $1086.9/QALY [95% CI: 1077.76:1096.24] compared with NSP, and $461.0/infection
averted [95% CI: 452.98:469.04] compared with OST. These results are consistent with previous studies.
Conclusions: Despite the inherent limitations of retrospective data, this study provides evidence that harm-reduction
interventions are a cost-effective way to reduce HIV prevalence. More research on into cost effectiveness in different
settings, and the availability of fiscal space for government uptake of programmes, is required.
Keywords: Harm reduction, Cost effectiveness analysis, Needle and syringe programme, Opioid substitution therapy,
Ukraine, Markov Monte Carlo simulation, Global FundBackground
There are an estimated 15.9 million injecting drug users
(IDUs) worldwide, 80% of whom live in developing and
transitional countries [1]. The concurrent epidemics of HIV
and injecting drug use have rapidly increased HIV preva-
lence [2], with 10% of HIV/Acquired Immunodeficiency
Syndrome (AIDS) cases worldwide attributed to IDUs [3,4].
HIV prevalence in Eastern Europe and Central Asia has
almost tripled since 2000 [1], to an estimated 1.4 million
people in 2011 [5]. The region is also home to 3.7 million
IDUs [1]. Ukraine’s HIV prevalence is the highest in Europe
and a 2010 study found that 50% of IDUs in Ukraine were
HIV positive [6]. The Global Fund has spent approximately
$20 m on harm reduction in the Ukraine [7].* Correspondence: sung.kim.11@ucl.ac.uk
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unless otherwise stated.Harm reduction interventions aim to reduce the harmful
results of drug use. Although there is no agreed definition,
a small number of interventions are commonly described
in the literature as “harm reduction” including; condom
provision, community based outreach, peer-led interven-
tions, needle and syringe programmes (NSP) and opioid
substitution therapy (OST) [8]. Needle and syringe pro-
grammes offer a clean needle and syringe to injecting drug
users (IDUs), while opioid substitution therapy (OST) re-
places heroin with a less addictive drug such as methadone
or buprenorphine under medical supervision. As IDUs
undergoing OST may continue drug use outside of the
programme [9], combining NSP with OST may be more
effective in reducing HIV transmission than a single inter-
vention [10]. This paper will focus only on three harm re-
duction strategies; NSP, OST, and combined therapy (NSP
and OST) based on the literature review.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of the relative cost effectiveness of harm reduction strat-
egies. A literature review on the cost-effectiveness of
harm reduction describes what is known, and what is
not. A cost-effectiveness analysis of harm-reduction is
then conducted using data from the Global Fund for the
Ukraine. The analysis compares NSP, OST and a com-
bined intervention. To the best of our knowledge, this is
the first study comparing a combined intervention with
NSP or OST alone, in any setting.
Literature review
The literature on harm reduction cost-effectiveness was
reviewed to summarize current evidence. Web of Science,
Econlit and Pubmed were the primary databases searched.
A supplementary search was conducted using Google
Scholar. Reference lists of identified papers were hand-
searched for further appropriate papers. The search terms
were: cost-effectiveness, HIV, NSP, OST, harm reduction,
needle and syringe, and methadone. Only papers published
in English, in peer-reviewed journals were considered.
The inclusion criteria were: 1) Studies should be about
harm reduction interventions i.e. NSP, OST, or combined
therapy; 2) Studies should be analyzed from a health eco-
nomic perspective 3) Studies should present data on either
effectiveness or cost, and 4) Studies should focus on HIV.
5) Papers not available in English or published before 1990
were excluded. The initial search identified 18 papers.
After reviewing titles and abstracts, 3 were excluded. After
reading the full papers, 3 further papers were excluded
and 3 were added following a hand search of the reference
lists. The final review includes 15 papers listed in Table 1,
two of which are literature reviews themselves.
This literature review summarizes the systematic review
papers [11,12] and then lists the papers published since
their publication [10,13-17,19,20,22-24]. One exceptional
case is the research by Van den berg et al. [21]. This study
was added to bolster the evidence around the combined
intervention because the majority of the papers since the
systematic reviews focus on a single therapy. Only one re-
trieved study by Degenhardt et al. [10] focused on the ef-
fectiveness of combined intervention of NSP and OST.
The first two papers in Table 1 are reviews of harm reduc-
tion strategies by Connock et al. [12] and Jones et al. [11].
Connock et al. [12] conducted a systematic review and cost
effectiveness analysis of OST. They conclude that metha-
done dominates buprenorphine, both of which are licensed
for use as opioid substitutes. Jones et al. [11] conducted a
systematic review of NSP. Jones et al. [11] conclude from
their review that in terms of reducing HIV incidence and
prevalence among IDUs, NSPs are cost-effective.
While the review papers aimed to explore the cost effect-
iveness of a single intervention, a number of studies con-
ducted since the reviews, have attempted to compare thesesingle interventions with an alternative. For example, Van
den berg et al. [21], (cited in the review by Jones et al.)
compared a combined intervention with incomplete harm
reduction. They concluded that combined intervention is
more cost effective than incomplete harm reduction. Van
den berg et al. [13] compared full harm reduction (NSP +
OST) vs incomplete harm reduction (NSP +OST). How-
ever, they assumed incomplete harm reduction always
offers OST, just changing ‘the dose of OST’. Therefore, pa-
tients who get incomplete harm reduction always get OST
as a base case. Likewise, Degenhardt et al. [10] compared
combined intervention (OST+NSP) with ART and found
that combined intervention of OST and NSP and ART
gained more effectiveness than either OST +NSP or ART.
All NSP studies that reported NSP as a primary inter-
vention used ‘no NSP and no intervention’ as a com-
parator. However, studies of OST show more varied
comparators; ‘no OST’ [15-17], combined ART interven-
tion [10,20], and buprenorphine [12].
Of the papers listed in Table 1, ten used either QALYs
gained or DALYs averted as a measure of outcome. All
of the papers estimated both cost per infection averted
and cost per either QALY or DALY.
In general, these studies suggest that harm reduction
interventions are cost effective and particular reference
is made to OST [18,19] and NSP [22,23]. These results
are derived mainly from a mathematical and epidemio-
logical modelling [14,15,22,23,25] rather than from co-
hort studies [21]. This review also highlights a gap in the
evidence regarding the relative cost effectiveness of
harm reduction strategies. It is necessary to compare
which mono-therapy (OST or NSP) is more cost effect-
ive, and whether mono-therapy is more cost effective
than combined intervention – whether or not ART is of-
fered. This is not because the provision of ART is unim-
portant, but because the literature has moved on to
evaluate the cost effectiveness of the provision of ART
with harm reduction – without first considering what is
the most cost effective harm reduction package. As de-
scribed above, there are studies arguing for the relative
cost effective of NSP [13], of OST [14] and of combined
intervention [10,20,21]. However, no study that we could
find compared the cost effectiveness of these three harm
reduction alternatives. To fill this evidence gap, we con-
duct a CEA of harm reduction comparing NSP, OST,
and combined intervention, using each intervention as a
comparator. Exclusion of ART from harm reduction in-
terventions appears to be feasible, considering the low
ART coverage among IDUs in the Ukraine, which was
26.7% in 2004 and 24% in 2008 [26,27].
Section 2: case study of the Ukraine
The largest IDU populations in Eurasia are in the Russian
Federation (1.8 million) and the Ukraine (296,000) [1].
Table 1 Summary of systematic review result
Study Comparator Intervention
Evaluated
Form of economic
analyses
Perspective taken Model used Time horizon Outcome measure
Jones et al. [11]† Cost utility (N = 12)
Cost benefit (N = 1)
Behavioural models using simplified
Bernoulli process (N = 4) simulated
the transmission (N = 2) the theory
of needle circulation originally
developed by Kaplan and O’Keefe
(N = 4)
HIV incidence (N = 11) HCV incidence
(N = 1) HIV and HCV incidence (N = 1)
Connock et al.
[12]†
Cost–utility (N = 5) Societal perspective (N=5)
healthcare system (N=6)
Markov (N = 3) Dynamic (N = 3)
Monte Carlo (N = 1)
QALY (N = 6)
Belani and
Muennig [13]
no NSP NSP Cost utility Societal Decision model 1 year Infection averted & QALYs
Wammes et al.
[14]
OST OST (coverage 5%
to 40%)
Cost effectiveness/
cost analysis
Societal Mathematical transmission model 20 year Infection averted
Guinness et al.
[15]
non intervention OST Cost utility Provider Mathematical model 3 year Infection averted & DALYs
Tran, Mills, et al.
[16]
non OST OST Cost utility Health service provider Real cohort data 9 month QALYs
Tran, Nguyen,
et al. [17]
non OST OST cost utility Vietnam health care
system
Decision analytical model 1 year Infection averted & QALYs
Tran, Ohinmaa,
et al. [18]
OST&ART OST Cost utility Vietnam health care
system
Decision tree monte carlo simulation 1 year Infection averted & QALYs
Connock et al.
[12]**
Buprenorphine OST (methadone
vs
buprenorphine)
Cost utility NHS Markov monte carlo simulation 1 year QALYs
Degenhardt
et al. [10]
ART,
NSP&OST&ART
Combined
(NSP&OST)
Cost effectiveness Transmission model 5 years Infection aveted
Alistar, Owens,
and Brandeau
[19]
OST&ART ART
alone
OST Cost utility Provider dynamic compartmental model 20 year Infection averted & QALYs
Li et al. [20] ART, VCT Combined
(NSP&OST)
Cost utility Mathematical 30 year Infection averted & QALYs
Van den berg
et al.* [21]
Methadone dose
or NEP use alone
Combined (NSP&
OST)
Not stated Cohort study 20 years Incidence rate ratio
Kwon et al. [22] no NSP NSP Cost utility Health sector Mathematical model lifetime Infection averted & QALYs
Zhang et al. [23] no NSP NSP Cost utility Societal Mathematical model 7 years Infection averted & DALYs
†Systematic review.
*included in Jones et al. [11].
**Connock et al. [12] carried out a systematic review and a cost effectiveness analysis in one paper.
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highest prevalence rate in Europe [6]. The Global Fund
has spent approximately $ 20 m on harm reduction in the
Ukraine since 2004 [7]. Considering that the Global Fund
disbursed US$ 361 million through 120 grants in 55 coun-
tries between 2002 and 2009 [28], the amount spent in the
Ukraine is significant for a single country. That said, while
the Global Fund provides significant international support
for harm-reduction programs [2,28], these investments
have seldom been evaluated.Methods
Consistent with previous research in this area [12,29],
this study uses a Markov model, assuming three states
of ‘infected’, ‘uninfected (well)’, and ‘dropped’. The model
is designed to estimate costs and outcomes in terms of
QALYs and HIV infections averted over 60 months, for
the three strategies. The model estimates uncertainty
using probability distributions. Monte Carlo simulation
was then carried out using these distributions to account
for uncertainty in the results of the model.
Figure 1 illustrates one cycle of the Markov decision
model in this study. ‘Infected’ status occurs when pa-
tients are confirmed as HIV positive while ‘uninfected’
occurs when patients are HIV negative. ‘Dropped’ means
that IDUs quit any harm reduction interventions they
were attending. It is assumed that there is no mortality
within the 5 year harm reduction period based on the
existing literature (Table 2). This assumption is consist-
ent with the approach used by Vickerman et al. [25]
(Table 2). As the objective of this study is to compare
the cost effectiveness of harm reduction strategies irre-
spective of ART provision, ART is not offered in any
intervention including ‘no intervention’.
A Markov Monte Carlo simulation with 10,000 itera-
tions was conducted. It is known that at least 440 itera-
tions should be run to be 95% sure that the estimate of
the mean of the output is accurate [36]. Consequently, it
can be said that 10,000 iterations are sufficient to get a
95% confidence interval. This figure of 10,000 iterations
is consistent with other research on HIV [37,38] and is
recommended for medical decision making generally
[39]. The main outcomes are expressed as cost effective-
ness ratios (CE) and incremental cost-effectiveness ratios
(ICERs).
Treeage software was used to construct the model.
Sensitivity analysis was carried out to account for uncer-
tainty in the cost data. Potential affordability of the three
strategies was assessed using probability sensitivity ana-
lysis (PSA) with the GDP of the Ukraine as a threshold.
Based on WHO recommendations, an intervention may
be considered cost effective if the cost per QALY is less
than the country’s GDP per capita [35,40]Interventions compared
ICER ¼ c1−c0
E1−E0
¼ c1
E1
C1 is the cost of the new intervention, and E1 is the ef-
fect of the new intervention, whereas C0 and E0 are the
cost and effect of the base case or comparator. Six cases
were considered in this study: NSP vs OST, NSP vs
NSP&OST, NSP vs no intervention, OST vs NSP&OST,
OST vs no intervention, NSP&OST vs no intervention.
The result is shown as a form of PSA in Figures 2 and 3.
The base case is a no intervention, in which IDUs do not
get any harm reduction intervention.
HIV incidence was obtained from previous literature.
Given the initial HIV prevalence [25], the effectiveness
of each intervention was estimated. HIV incidence and
infections averted, were calculated with the following
formula [16,30]:
HIV incidence ¼ S 1−p 1−βð Þa 1−γð Þ þ 1−pð Þn
h i
where S = total no of susceptible individuals (IDUs)
α = reduction in frequency of drug injections per day
from the cohort data
β = Pr of transmission
γ= reported using sterile injection equipment or con-
dom or methadone
n = number of days follow up
p = HIV prevalence among IDUs
It was assumed that IDUs inject needles and syringes
400 times per year [10,41] and that they inject con-
stantly for the entire program period. The HIV preva-
lence rate of IDUs for each intervention were calculated
using parameters from different papers [10,19,25], as-
suming that they are already getting each intervention
as data was not available for HIV prevalence rate. The
values of alpha and gamma are shown as a proportion,
and corresponding parameter values are presented in
Table 2.
Distribution of parameters
To implement Monte Carlo simulation, the costs of
each intervention were estimated based on gamma dis-
tribution, which is nonnegative and allows the max-
imum likelihood estimate of the population mean to be
the sample mean (Table 2) [42]. The probability distri-
bution of each intervention was estimated with beta
distribution, the value of which is between 0 and 1.
Normal distribution was used for utilities of outcome
for interventions. For the discount rate, a uniform dis-
tribution between 0 and 1 was used.
Figure 1 Decision model.
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In this study, transition probabilities for the ‘infected’,
’uninfected (well)’, and ‘dropped’ state are shown in
Table 2. QALYs for each state were obtained from exist-
ing research [12,25].
Cycle times of 1 month or 1 year are generally used in
Markov model for chronic diseases [43]. Although 1 year
can be used for HIV [44], IDUs can drop out of theinterventions sooner. Therefore, a cycle length of 1 month
is more appropriate for this model. Since each cycle in the
model is 1 month, these transition probabilities were ad-
justed for a monthly base.
The prevalence rates of each intervention were ob-
tained from previous research that calculated the rates
considering needle sharing between IDUs, condom use
and sexual behaviours [25]. The dropout rates at each
Table 2 Model parameters
Simulation parameters
HIV incidence Base case value Duration Distribution Source
Number of injections 400.00 1 year Degenhardt et al. [10] Aceijas et al. [3]
reduction in frequency of drug injections per
day from the cohort data
0.85 1 year Alistar, Owens, and Brandeau [19]
Pr of transmission 0.01 1 year Gouws et al. [30]
using sterile injection equipment or condom
or methadone
0.90 1 year Assumed based on Cao et al. [31]; Vickerman
et al. [25]; Alistar et al. [19]
number of days follow up 60 cycle(5 years) 60 months
(treatment)
Global Fund [7]
HIV prevalence among IDUs(NSP) 0.43 1 year Calculated using Vickerman et al. [25]
HIV prevalence among IDUs(OST) 0.28 1 year Calculated using Vickerman et al. [25]; Alistar,
Owens, and Brandeau [19]
HIV prevalence among IDUs(NSP&OST) 0.18 1 year Calculated using Degenhardt et al. [10]
Decrease in HIV incidence(NSP) 0.22 1 year Vickerman et al. [25]
Decrease in HIV incidence (OST) 0.53 1 year Alistar, Owens, and Brandeau [19]
Decrease in HIV incidence (NSP&OST) 0.66 1 year Degenhardt et al. [10]
Probability
Pr(attend to intervention) 0.0750 1 cycle Beta Assumed
Pr(mortality) if no intervention 0.03 1 cycle Beta Vickerman et al. [25]
Pr(infected) if no intervention 0.0446 1 cycle Beta Vickerman et al. [25]
Pr(well) if no intervention 0.0388 1 cycle Beta calculated
Pr(drop) from NSP&OST 0.0083 1 cycle Beta Calculated Pr(attend to intervention)
Pr(infected) from NSP&OST 0.0003 1 cycle Beta Degenhardt et al. [10]
Pr(well) from NSP&OST 0.9914 1 cycle Beta Calculated
Pr(drop) from NSP 0.0083 1 cycle Beta Calculated Pr(attend to intervention)
Pr(infected) from NSP 0.0005 1 cycle Beta Vickerman et al. [25]
Pr(well) from NSP 0.9912 1 cycle Beta Calculated
Pr(drop) from OST 0.0083 1 cycle Beta Calculated Pr(attend to intervention)
Pr(infected) from OST 0.0004 1 cycle Beta Alistar, Owens, and Brandeau[19]
Pr(well) from OST 0.9913 1 cycle Beta Calculated
Pr(infected) if dropped from intervention 0.0446 1 cycle Beta Vickerman et al. [25]
Pr(well) if dropped from intervention 0.9554 1 cycle Beta Calculated
Pr(drop) if infected from NSP&OST 0.0102 1 cycle Beta Yin et al. [32]; Jones et al. [11]
Pr(attend) if infected from NSP&OST 0.9898 1 cycle Beta Calculated
Pr(drop) if infected from NSP 0.0196 1 cycle Beta Jones et al. [11]
Pr(attend) if infected from NSP 0.9804 1 cycle Beta Calculated
Pr(drop) if infected from OST 0.0433 1 cycle Beta Yin et al. [32]
Pr(well) if infected from OST 0.9567 1 cycle Beta Calculated
QOL
NSP 0.85 Normal Vickerman et al. [33]
OST 0.74(average value
for 54 week)
Normal Connock et al. [12]
NSP & OST 0.95 Normal Vickerman et al. [33]
Infected(dropped) 0.63 Normal Connock et al. [12]
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Table 2 Model parameters (Continued)
Cost
NSP
unit cost per patient 151.14 1 year gamma Global Fund [7]
Fixed 1197008.80 1 year gamma Estimated from the Global Fund grant proposal
OST
unit cost per patient 1752.00 1 year gamma WHO medical database
Fixed 700050.60 1 year gamma Estimated from the Global Fund grant proposal
NSP&OST
unit cost per patient(per year) 1903.14 1 year gamma Global Fund [7], WHO medical database
Fixed 168286.96 1 year gamma Assumed from the Global Fund grant proposal
Other parameters
Consumer price index(CPI) 1.5680 WorldBank [34]
Time horizon 5 years WHO [35]
Discount rate for cost 0.03 Uniform WHO [35]
Discount rate for outcome 0.03 Uniform WHO [35]
Population(NSP) 11000.00 Global Fund [7]
Population(OST) 5000.00 Global Fund [7]
Population(NSP & OST) 6000.00 Global Fund [7]
Initial HIV prevalence among IDUs 0.53 1 year Vickerman et al. [25]
IDU mortality rate per 1000 person-years 0.4 1 year Vickerman et al. [25]
Figure 2 Probabilistic sensitivity analysis(Y axis: Incremental cost X axis: HIV infection averted, Dotted line: WTP = GDP per capita of
the Ukraine).
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Figure 3 Probabilistic sensitivity analysis(Y axis: Incremental cost X axis: QALYs, Dotted line WTP = GDP of the Ukraine).
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research [11,32] (Table 2).
Costs
Cost data were collected from the Global Fund website
(www.theglobalfund.org). The Global Fund’s intervention
in the Ukraine includes various harm-reduction packages
[28]. In addition, other interventions were carried out sim-
ultaneously including public health education campaigns
around harm reduction for IDUs, and other complemen-
tary activities. As a result, the exact proportion allocated
to the combined intervention is not clear. For the purposes
of this analysis then, it was conservatively assumed that
the variable cost of the combined strategy is simply the
sum of the variable costs for NSP and OST. Alistar et al.
[19] calculated the cost of combined intervention of OST
and ART in this way. They assumed identical staff costs
such as counselling costs for both interventions and that
the costs of the combined intervention are the sum of the
variable costs for OST and ART. Staff costs and other de-
livery costs were included in start-up costs for each cycle.
The variable costs of each intervention were annualised.
Indirect costs, such as productivity loss, were not taken
into account in this study and noted as a limitation of this
analysis. Budgets for Round 6 (2006–2010) were also used
for the combined intervention, although OST alone andthe combined intervention was simultaneously imple-
mented. This limitation in the cost data will be tested with
sensitivity analysis.
The summarized grant data for the Ukraine is presented
in Table 3-a. Costs per cycle were estimated based on the
summarized data in Table 3-b, which describe how the
harm reduction interventions of NSP and OST were con-
ducted for 5 years. The variable cost of NSP for each cycle
in the Ukraine comprises disposable syringes, needles, dis-
infectant solutions, and alcohol wipes [7]. The variable
cost of OST is from the WHO medical database, using the
price from Pharmascience.inc [7].
Costs were incurred in United States dollars (USD)
and adjusted for inflation to 2011 values using the con-
sumer price index (CPI) for the Ukraine from the World
Bank [45]. All costs other than the variable costs of NSP
and OST were classified as start-up costs (Table 3-b),
which are generated at each Markov cycle of 1 month ir-
respective of the number of patients. The information
regarding the total number of patients to calculate a cost
per patient was obtained from the Global Fund website
[46] and is presented in Table 2.
Discounting, perspective and time horizon
The intervention’s benefits were evaluated over the dur-
ation of the grant period i.e. from the start of 2002 to
Table 3 Cost data
a) Grant data Summary
Intervention Year 1 Year 2 Year 3 Year 4 Year 5 Total
Ukraine harm reduction_syringe 522,600 1,372,411 1,901,061 1,900,411 1,951,061 7,647,544
Substitution therapy 1,127,125 1,443,544 3,099,845 3,194,531 3,395,208 12,260,253
b) Cost per cycle
Cost per 1 cycle NSP OST Combined
Starting up cost 99750.73 58337.55 14023.91
Cost per patient 2.52 29.20 31.72
Total cost per 1 cycle
Cost per patient 11.59 40.87 34.06
*All figures in table 3 is USD.
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year. As the World Health Organisation (WHO) recom-
mended, an identical discount rate of 3% was applied to
both costs and effectiveness. A provider perspective was
applied.
Population
Using data from the literature, it was assumed that half
of IDUs attending the interventions were infected at the
outset [1,25] (Table 2) and the average age was assumed
to be 39 [47].
Results
The results of the Markov Monte Carlo simulation are
given with 95% confidence intervals in Table 4. The re-
sult of costs and effectiveness of deterministic analysis is
located within the confidence interval of probabilistic
analysis, showing the robustness of the result regarding
the parameters for this model.
Combined therapy of NSP and OST averted the most in-
fections (1848 HIV infections averted). After this, OST
alone averted the most infections (1053 HIV infections
averted). Combined therapy averted more infections than
the sum of OST alone and NSP alone (1848 HIV infection
averted vs 1559 HIV infection averted). Considering QALY
gains, combined therapy still gained most (4183.5 QALYs).
After this, NSP alone gained slightly more QALYs than
OST alone (2970 QALYs vs 2599 QALYs).
Although combined therapy strictly dominated in terms
of benefits, NSP alone was most cost effective at $487.4/
infection averted and $83.3/QALY gained compared with
combined therapy of NSP and OST together at $851.6/
infection averted and $373.7/QALYs (Table 4). OST alone
had the highest cost effectiveness ratios at $1145.9/
infection averted and $459.9/QALYs.
Sensitivity analysis
The costs of combined NSP and OST are uncertain due to
the limitations of the cost data, which do not explicitlystate the total costs of the combined intervention. Conse-
quently, one-way sensitivity analysis was conducted to
relax this limitation. The uncertainty of both effectiveness
and costs was examined using PSA. The three strategies
were compared with a single therapy in Table 5.
Irrespective of the variation in the starting costs of
combined intervention, the results are consistent at both
outcome measures. It was found that the variation in the
start up costs of combined intervention did not affect
the rank of strategies in terms of ICER. Although the
ICER of combined intervention varies between $428 and
$461/infection averted, the rank of ICER for each inter-
vention did not change. Similarly, when presented in
QALYs, the ICER of each intervention did not change
regardless of the variation in starting up costs.
On the other hand, it was found that the variable cost of
OST can affect the relative rank of strategies. At the lower
end of OST, OST was most cost effective strategy at both
QALYs and infection averted. The ICER of combined inter-
vention [$428-$461/infection averted] was slightly lower
than the ICER of NSP [$487/infection averted] although
NSP alone is more cost effective. This results from the fact
that OST has ‘extended dominance’ in terms of HIV infec-
tions averted and so combined intervention was compared
with OST instead of NSP.
In brief, this result relaxes the uncertainty in the start
up cost of combined intervention, and offers supporting
evidence that the combined intervention and NSP alone
are preferred strategies to OST alone. Also, the high
variable cost of OST makes OST alone, a less cost effect-
ive strategy.
Probability sensitivity analysis
Figures 2 and 3 shows the results of probabilistic sensitiv-
ity analysis with 95% confidence interval using Monte-
Carlo simulation.
The result of combined intervention vs NSP alone is lo-
cated in the first quadrant, suggesting that the combined
intervention is incrementally cost effective compared with
Table 4 10,000 times Monte Carlo simulation results and a deterministic result of cost and effectiveness
Infection averted Monte Carlo Simulation Deterministic
Combined NSP OST Combined NSP OST
Cost 1,574,559.00 247,108.68 1,206,760.80 1,565,967.17 247,148.20 1,199,134.00
Std 580,415.89 67,045.82 419,480.75
Upper CI(95%) 1,585,935.20 248,422.78 1,214,982.60
Lower CI(95%) 1,563,182.90 245,794.58 1,198,539.00
Effect 1,848.76 506.98 1,053.10 1,848.74 506.98 1,053.03
Std 6.78 5.33 5.39
Upper CI(95%) 1,848.89 507.08 1,053.21
Lower CI(95%) 1,848.63 506.88 1,052.99
CE 851.68 487.41 1,145.91 847.05 487.49 1,138.75
Std 95.06 54.01 128.57
Upper CI(95%) 853.55 488.47 1,148.43
Lower CI(95%) 849.82 486.35 1,143.39
QALY
combined NSP OST combined NSP OST
Cost 1,563,571.10 247,577.10 1,195,319.80 1,565,967.17 247,148.20 1,199,134.00
Std 579,705.31 66,864.85 418,960.03
Upper CI(95%) 1,574,933.30 248,887.65 1,203,531.40
Lower CI(95%) 1,552,208.90 246,266.55 1,187,108.10
Effect 4,183.51 2,970.21 2,599.08 4,183.51 2,970.21 2,599.04
Std 7.47 5.69 5.71
Upper CI(95%) 4,183.66 2,970.32 2,599.19
Lower CI(95%) 4,183.36 2,970.10 2,598.97
CE 373.75 83.35 459.90 374.32 83.21 461.38
Std 95.06 54.01 128.57
Upper CI (95%) 374.57 83.55 460.93
Lower CI (95%) 372.92 83.15 458.87
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bined intervention may in fact cost less than OST as a sin-
gle therapy and therefore be the dominant strategy when
compared with OST: 31% of results are in the fourth
(south east) quadrant. This means that the probability that
the combined intervention is more effective at higher cost,
in terms of infection averted, than OST alone is 69% (first
quadrant).
Irrespective of the outcome measures, the combined
intervention is located below the line of willingness to
pay (WTP) for the Ukraine.
Conclusion
In this paper, an updated systematic review of the cost-
effectiveness of harm reduction highlighted a gap in
existing evidence: the lack of an incremental approach
to comparing the cost effectiveness of combined versus
mono-therapy. To fill the evidence gap, this study has
attempted to determine the cost-effectiveness of harmreduction by the Global Fund in the Ukraine. A Markov
Monte Carlo Model was used to conduct n incremental
economic analysis comparing 3 harm-reduction inter-
ventions with one another and with no intervention; i.e.
NSP alone, OST alone and combined OST and NSP.
The analysis found that all interventions were cost ef-
fective in terms of QALYs gained and HIV infections
averted. NSP alone was the most cost effective and OST
alone was the least cost effective option. While com-
bined therapy did not have the lowest cost effectiveness
ratio, it was significantly more effective in both outcome
measures than any alternative. The relatively high vari-
able cost of OST ($31.72 per patient per cycle) explains,
to a large extent, why the combined strategy is not as
cost effective as NSP alone.
The result that NSP is most cost-effective, is consist-
ent with previous research on harm-reduction [19,25].
NSP alone ($83.35/QALY in Table 4) is shown to be
more cost-effective in the Ukraine than in Australia
Table 5 Sensitivity analysis
Averted Lower end ICER CI (95%) Higher End ICER CI (95%) Comparator
Variable_NSP No intervention 0.00 0.00 2.52 0.00
Variable_NSP NSP 0.00 296.71 293.40:298.60 2.52 487.49 484.89:490.09 vs no intervention
Variable_NSP OST 0.00 1920.53 1911.68:1929.38 2.52 1743.40 1734.55:1752.25 vs NSP
Variable_NSP NSP and OST 0.00 461.01 452.98:469.04 2.52 461.01 452.98:469.04 vs OST
Variable_OST No intervention 0.00 0.00 29.20 0.00
Variable_OST OST 0.00 83.17 82.73:83.61 29.20 1743.40 1734.55:1752.25 vs NSP
Variable_OST NSP 0.00 −292.22 (−294.6): (−289.4) 29.20 487.49 484.89:490.09 vs no intervention
Variable_OST NSP and OST 0.00 1857.95 29.20 461.01 452.98:469.04 vs OST
Startingcost_NSP No intervention 0.00 0.00 99750.75 0.00
Startingcost_NSP NSP 0.00 190.78 187.4:192.6 99750.75 487.49 484.89:490.09 vs no intervention
Startingcost_NSP OST 0.00 2018.89 2009.95:2027.65 99750.75 1743.40 1734.55:1752.25 vs NSP
Startingcost_NSP NSP and OST 0.00 461.01 452.98:469.04 99750.75 461.01 452.98:469.04 vs OST
Startingcost_combined No intervention 0.00 0.00 14023.92 0.00
Startingcost_combined NSP 0.00 487.49 484.89:490.09 14023.92 487.49 484.89:490.09 vs no intervention
Startingcost_combined OST 0.00 1743.40 1734.55:1752.25 14023.92 1743.40 1734.55:1752.25 vs NSP
Startingcost_combined NSP and OST 0.00 428.49 419.96:436.03 14023.92 461.01 452.98:469.04 vs OST
Startingcost_OST No intervention 0.00 0.00 58337.53 0.00
Startingcost_OST NSP 0.00 487.49 484.89:490.09 58337.53 487.49 484.89:490.09 vs no intervention
Startingcost_OST OST 0.00 1583.01 1574.15:1591.85 58337.53 1743.40 1734.55:1752.25 vs NSP
Startingcost_OST NSP and OST 0.00 571.08 562.97:579.03 58337.53 461.01 452.98:469.04 vs OST
QALYs
Variable_NSP No intervention 0.00 0.00 2.52 0.00
Variable_NSP NSP 0.00 50.65 50.2:51.08 2.52 83.21 82.76:83.65 vs no intervention
Variable_NSP OST 0.00 −2825.37 (−2836.71):
(−2793.29)
2.52 −2564.79 (−2585.71):
(−2542.29)
vs NSP
Variable_NSP NSP and OST 0.00 1166.69 1150.94:1181.07 2.52 1086.97 1077.76:1096.24 vs NSP
Variable_OST No intervention 0.00 0.00 29.20 0.00
Variable_OST OST 0.00 33.70 30.63:36.75 29.20 83.21 79.94:86.06 vs no intervention
Variable_OST NSP 0.00 429.90 419.96:436.03 29.20 −2564.79 (−2585.71):
(−2542.29)
vs OST
Variable_OST NSP and OST 0.00 1086.97 1077.76:1096.24 29.20 1086.97 1077.76:1096.24 vs NSP
Startingcost_combined No intervention 0.00 0.00 14023.92 0.00
Startingcost_combined NSP 0.00 83.21 82.76:83.65 14023.92 83.21 82.76:83.65 vs no intervention
Startingcost_combined OST 0.00 −2564.79 (−2585.71):
(−2542.29)
14023.92 −2564.79 (−2585.71):
(−2542.29)
vs NSP
Startingcost_combined NSP and OST 0.00 1065.64 1049.93:1080.07 14023.92 1086.97 1077.76:1096.24 vs NSP
Startingcost_NSP No intervention 0.00 0.00 99750.75 0.00
Startingcost_NSP NSP 0.00 32.56 29.49:35.62 99750.75 83.21 82.76:83.65 vs no intervention
Startingcost_NSP OST 0.00 −2970.06 (−2991.71):
(−2948.29)
99750.75 −2564.79 (−2585.71):
(−2542.29)
vs NSP
Startingcost_NSP NSP and OST 0.00 1210.95 1194.93:1225.06 99750.75 1086.97 1077.76:1096.24 vs NSP
Startingcost_OST No intervention 0.00 0.00 58337.53 0.00
Startingcost_OST NSP 0.00 83.21 82.76:83.65 58337.53 83.21 82.76:83.65 vs no intervention
Startingcost_OST OST 0.00 −2328.83 (−2350.54):
(−2307.12)
58337.53 −2564.79 (−2585.71):
(−2542.29)
vs NSP
Startingcost_OST NSP and OST 0.00 1086.97 1077.76:1096.24 58337.53 1086.97 1077.76:1096.24 vs NSP
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QALY] [48], However, the cost effectiveness ratio of
NSP alone in this study, at $487.41 per HIV infection
averted, is significantly higher than that from another
study in the Ukraine study [$97–162 per HIV infection
averted] [25]. OST, at $459.90 per QALY, was slightly
more cost-effective than other analyses for the Ukraine
suggest [$530/QALY] [19]. Regardless, OST was a dom-
inated strategy for both outcome measures and this is
attributed to the high variable cost of OST. The results
of the sensitivity analysis support this conclusion.
From the result of PSA, the samples are located below
the slope of willingness to pay (WTP). Considering that
the GDP of the Ukraine was $3,615 in 2011 [34], all
three interventions were found to be located below the
cost effectiveness threshold suggested by the WHO [35].
As a result, and given the significant dominance of com-
bined therapy in terms of benefits, this is may be the
preferred strategy in the Ukraine context. That said, a
discussion about affordability and the ethics of selecting
a less effective strategy may be warranted in this context.
Some caveats exist in this study and the generali-
zability of the findings, which should be noted. Firstly,
the start-up costs of combined intervention are uncer-
tain. This makes it more important to measure uncer-
tainty and sensitivity in costs. Also, the probability of
transmission used in this study assumes normal IDUs.
However, depending on the IDUs’ status (i.e. sex workers
or men who have sex with men (MSM)), the probability
will vary. Likewise, the assumption that the variable cost
of the combined strategy is simply the sum of the vari-
able costs for NSP and OST can be relaxed with more
detailed information regarding cost data. Another cau-
tion is that the effectiveness parameters, such as drop-
out rates, will vary depending on how an intervention is
implemented in practice. Therefore, the ‘dominance’ of
each strategy over comparators should be carefully inter-
preted. Also, the GDP threshold is a weak indicator of
affordability and more work is needed in this area.
More detail on the number of IDUs reached by Global
Fund NSP and OST programs would further improve the
accuracy of estimates. With more evidence regarding the
effectiveness of harm reduction programs, including those
supported by the Global Fund, greater support for effect-
ive – and cost effective - harm reduction can be fostered.
Abbreviation
NSP: Needle and syringe programme; OST: Opioid substitution therapy;
ART: Anti-retroviral therapy; IDUs: Injecting drug users.
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